SeekingAlphaAugust 18, 2026 at 1:43 AM NY17 days ago
Artiva Biotherapeutics: Targeting A Potentially Lucrative Niche
Artiva Biotherapeutics advances AlloNK NK cell therapy for refractory rheumatoid arthritis; early data shows 71% ACR50 and safety. Click for more on ARTV stock.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha
Companies in This Story
Related Stories
Which dow jones stocks are moving on Friday?
ChartMill2 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill2 hours ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo2 hours ago
Sector Update: Financial
Yahoo4 hours ago
Should You Buy, Sell or Hold PVH Stock Post Q2 Earnings?
Yahoo4 hours ago